Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-positive Breast Cancer Patients: A Single Institution Experience

INTRODUCTION: Pertuzumab and trastuzumab are monoclonal antibodies used for treating HER2-positive breast cancer. These anti-HER2 antibodies may induce infusion reactions (IR), mainly upon first administration. We investigated factors predicting IR in the initial pertuzumab treatment for HER2-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsuji, Kazutaka, Tanabe, Masahiko, Morizono, Arisa, Harada, Mayumi, Sato, Ayaka, Niwa, Takayoshi, Nishioka, Kotoe, Seto, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908404/
https://www.ncbi.nlm.nih.gov/pubmed/36793527
http://dx.doi.org/10.31662/jmaj.2022-0132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908404/
https://www.ncbi.nlm.nih.gov/pubmed/36793527
http://dx.doi.org/10.31662/jmaj.2022-0132

Ejemplares similares